- Home
- YI vs TARA Comparison
YI vs TARA Comparison
Compare YI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- TARA
- Stock Information
- Founded
- YI 2010
- TARA N/A
- Country
- YI China
- TARA United States
- Employees
- YI N/A
- TARA N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YI Consumer Staples
- TARA Health Care
- Exchange
- YI Nasdaq
- TARA Nasdaq
- Market Cap
- YI 64.4M
- TARA 52.4M
- IPO Year
- YI N/A
- TARA N/A
- Fundamental
- Price
- YI $0.63
- TARA $2.47
- Analyst Decision
- YI
- TARA Strong Buy
- Analyst Count
- YI 0
- TARA 2
- Target Price
- YI N/A
- TARA $24.00
- AVG Volume (30 Days)
- YI 111.3K
- TARA 235.4K
- Earning Date
- YI 11-27-2024
- TARA 11-12-2024
- Dividend Yield
- YI N/A
- TARA N/A
- EPS Growth
- YI N/A
- TARA N/A
- EPS
- YI N/A
- TARA N/A
- Revenue
- YI $2,026,540,888.00
- TARA N/A
- Revenue This Year
- YI $61.85
- TARA N/A
- Revenue Next Year
- YI N/A
- TARA N/A
- P/E Ratio
- YI N/A
- TARA N/A
- Revenue Growth
- YI 0.38
- TARA N/A
- 52 Week Low
- YI $0.55
- TARA $1.04
- 52 Week High
- YI $2.34
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- YI 37.59
- TARA 57.56
- Support Level
- YI $0.65
- TARA $2.43
- Resistance Level
- YI $0.70
- TARA $2.74
- Average True Range (ATR)
- YI 0.05
- TARA 0.19
- MACD
- YI -0.01
- TARA -0.00
- Stochastic Oscillator
- YI 11.59
- TARA 45.23
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).